{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039773","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.609658+00:00","generated_at":"2026-06-12T02:07:08.700628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291","bullets":["Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.","Cash, equivalents and securities $909.5M at June 30, 2023, up from $644.9M at Dec 31, 2022.","FY 2023 GAAP net loss guidance $360M–$400M; cash expected to fund operations into 2025.","Planning pivotal single-agent trials for RMC-6236; combination trial with RMC-6291 starting in early 2024.","Clinical data for RMC-6236 and RMC-6291 to be presented at ESMO and Triple Meeting in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039773","json":"https://secwatch.observer/filing/0000950170-23-039773.json","markdown":"https://secwatch.observer/filing/0000950170-23-039773.md","text":"https://secwatch.observer/filing/0000950170-23-039773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/rvmd-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:07:08.700628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b518f88762e33689b03a7ba6fb2ffea0bce974d0","claim":"Revolution Medicines, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}